Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety Study of Albuterol Spiromax® in Subjects With Asthma

ClinicalTrials.gov ID: NCT01698320

Public ClinicalTrials.gov record NCT01698320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax® device performance through the life of the device during the study.

Study identification

NCT ID
NCT01698320
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
364 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2012
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013
Last update posted
Aug 18, 2015

2012 – 2013

United States locations

U.S. sites
30
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
Teva Investigational Site 10169 Huntington Beach California
Teva Investigational Site 10157 San Diego California
Teva Investigational Site 10148 Denver Colorado
Teva Investigational Site 10159 Denver Colorado
Teva Investigational Site 10158 Miami Florida
Teva Investigational Site 10168 Miami Florida
Teva Investigational Site 10154 Gainesville Georgia
Teva Investigational Site 10161 Louisville Kentucky
Teva Investigational Site 10162 Bethesda Maryland
Teva Investigational Site 10166 Wheaton Maryland
Teva Investigational Site 10151 Minneapolis Minnesota
Teva Investigational Site 10142 Plymouth Minnesota
Teva Investigational Site 10152 St Louis Missouri
Teva Investigational Site 10146 Bellevue Nebraska
Teva Investigational Site 10160 Skillman New Jersey
Teva Investigational Site 10144 Rochester New York
Teva Investigational Site 10141 High Point North Carolina
Teva Investigational Site 10153 Raleigh North Carolina
Teva Investigational Site 10147 Canton Ohio
Teva Investigational Site 10143 Cincinnati Ohio
Teva Investigational Site 10167 Sylvania Ohio
Teva Investigational Site 10150 Eugene Oregon
Teva Investigational Site 10156 Portland Oregon
Teva Investigational Site 10155 El Paso Texas
Teva Investigational Site 10149 New Braunfels Texas
Teva Investigational Site 10145 San Antonio Texas
Teva Investigational Site 10170 San Antonio Texas
Teva Investigational Site 10163 Burke Virginia
Teva Investigational Site 10165 Seattle Washington
Teva Investigational Site 10164 Greenfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01698320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01698320 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →